Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Martin H. Dreyling
Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
A Method for Screening Arrayed Cosmid Libraries With Mega Insert Yeast Artificial Chromosomes
Nucleic Acids Research
Genetics
Related publications
A Multicentre Study of Primary Breast Diffuse Large B-Cell Lymphoma in the Rituximab Era
British Journal of Haematology
Hematology
The Rituximab Maintenance Therapy Improves Prognosis of Transformed Diffuse Large B Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Rituximab in the Treatment of B-Cell Non-Hodgkin Lymphoma, Focus on Outcomes and Comparative Effectiveness
ClinicoEconomics and Outcomes Research
Health Policy
Economics
Econometrics
Finance
A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Regulation of CD20 in Rituximab-Resistant Cell Lines and B-Cell Non-Hodgkin Lymphoma
Clinical Cancer Research
Cancer Research
Oncology
Subcutaneous Rituximab in B-Cell Non-Hodgkin Lymphoma: A Single-Center Experience
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
The Kyoto Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma in the Rituximab Era
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Sandoz Rituximab for Treatment of Diffuse Large B-Cell Lymphoma: Interim Safety Results of the Non-Interventional, Observational, Multicenter, Open-Label Reflect Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Rituximab and Autologous Stem-Cell Transplantation for High-Risk Diffuse Large B-Cell Lymphoma – Authors' Reply
The Lancet Oncology
Oncology
